Showing results (121-130 of 134) with videos related to
Sort By:
Pageof 14
The Journal of Molecular Diagnostics : JMD|August 11, 2007
DNA degradation test predicts success in whole-genome amplification from diverse clinical samplesFengfei Wang, Lilin Wang, Christine Briggs, et al.Clinical Chemistry|January 3, 2025
Impact of Higher Cell-Free DNA Yields on Liquid Biopsy Testing in Glioblastoma PatientsJ Bryan Iorgulescu, Timothy Blewett, Kan Xiong, et al.Nature Communications|April 11, 2020
Author Correction: Image-guided radiotherapy platform using single nodule conditional lung cancer mouse modelsGrit S Herter-Sprie, Houari Korideck, Camilla L Christensen, et al.Nature Communications|December 19, 2014
Image-guided radiotherapy platform using single nodule conditional lung cancer mouse modelsGrit S Herter-Sprie, Houari Korideck, Camilla L Christensen, et al.Medrxiv : the Preprint Server for Health Sciences|February 20, 2025
Immediate postoperative minimal residual disease detection with MAESTRO predicts recurrence and survival in head and neck cancer patients treated with surgeryEdward S Sim, Justin Rhoades, Kan Xiong, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 20, 2025
Early Postoperative Minimal Residual Disease Detection with MAESTRO Is Associated with Recurrence and Worse Survival in Patients with Head and Neck CancerEdward S Sim, Justin Rhoades, Kan Xiong, et al.Oncotarget|December 5, 2015
Metastasis-associated MCL1 and P16 copy number alterations dictate resistance to vemurafenib in a BRAFV600E patient-derived papillary thyroid carcinoma preclinical modelMark Duquette, Peter M Sadow, Amjad Husain, et al.Nature Biomedical Engineering|March 18, 2022
Massively parallel enrichment of low-frequency alleles enables duplex sequencing at low depthGregory Gydush, Erica Nguyen, Jin H Bae, et al.JCI Insight|October 5, 2016
Synergy of radiotherapy and PD-1 blockade in Kras-mutant lung cancerGrit S Herter-Sprie, Shohei Koyama, Houari Korideck, et al.Medrxiv : the Preprint Server for Health Sciences|July 30, 2026
Minimal Residual Disease via circulating tumor DNA Predicts Exceptional Response in HER2-Positive Metastatic Breast CancerStefania Morganti, Catherine Song, Ningxuan Zhou, et al.Pageof 14